リキッドバイオプシー市場は、非侵襲的診断の需要の増加に牽引されて、予測期間中に247億ドルに達すると予想されます。リキッドバイオプシーは、従来の組織生検に代わる低侵襲性の利点を有するため、さまざまな診断目的での使用が増えています。世界的ながん症例が増加し続ける中、疾患を早期に検出・監視できるツールの必要性が高まっており、リキッドバイオプシーの需要が高まっています。さらに、PCR、NGS、デジタルドロップレットPCRなどの技術の進歩により、リキッドバイオプシーの精度と感度が向上し、市場の成長がさらに促進されます。また、新たな技術の進歩によって、リキッドバイオプシーはより正確で手頃な価格になり、医療従事者や患者にとってより身近なものとなっています。
目次
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Liquid Biopsy Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Liquid Biopsy Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Liquid Biopsy Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porter's Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Liquid Biopsy Market
10.1. Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Liquid Biopsy Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Product
11.3.1.1. Services
11.3.1.1.1. By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2. Kits & Reagents
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2. Market Share (%) 2024A-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.3. Platforms & Instruments
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2. Market Share (%) 2024A-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Circulating Biomarker
11.3.2.1. Circulating Tumor DNA
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2. Market Share (%) 2024A-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Circulating Tumor Cell
11.3.2.2.1. By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.3. Extracellular Vesicles
11.3.2.3.1. By Value (USD Million) 2024A-2034F
11.3.2.3.2. Market Share (%) 2024A-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.4. Others
11.3.2.4.1. By Value (USD Million) 2024A-2034F
11.3.2.4.2. Market Share (%) 2024A-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3. By Technology
11.3.3.1. Polymerase Chain Reaction (PCR)
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2. Market Share (%) 2024A-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Next-Generation Sequencing (NGS)
11.3.3.2.1. By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Cytometry
11.3.3.3.1. By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Digital PCR
11.3.3.4.1. By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4. By Application
11.3.4.1. Diagnosis and Screening
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2. Market Share (%) 2024A-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Treatment Monitoring
11.3.4.2.1. By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.3. Prognosis and Recurrence Monitoring
11.3.4.3.1. By Value (USD Million) 2024A-2034F
11.3.4.3.2. Market Share (%) 2024A-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.4. Treatment Selection
11.3.4.4.1. By Value (USD Million) 2024A-2034F
11.3.4.4.2. Market Share (%) 2024A-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024A-2034F
12. North America Liquid Biopsy Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Product
12.3.2. By Circulating Biomarker
12.3.3. By Technology
12.3.4. By Application
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Liquid Biopsy Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Product
13.3.2. By Circulating Biomarker
13.3.3. By Technology
13.3.4. By Application
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Liquid Biopsy Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Product
14.3.2. By Circulating Biomarker
14.3.3. By Technology
14.3.4. By Application
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Liquid Biopsy Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Product
15.3.2. By Circulating Biomarker
15.3.3. By Technology
15.3.4. By Application
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Liquid Biopsy Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Product
16.3.2. By Circulating Biomarker
16.3.3. By Technology
16.3.4. By Application
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Guardant Health, Inc.
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.2. QIAGEN N. V.
18.3. Natera, Inc.
18.4. Singular Genomics Systems, Inc.
18.5. Exosome Diagnostics, Inc.
18.6. Illumina, Inc.
18.7. Asuragen, Inc.
18.8. MDxHealth SA
18.9. Thermo Fisher Scientific Inc
18.10. Epigenomics AG
18.11. Sysmex Corporation
18.12. Circulating Cell-Free Genome Atlas (CCGA)
18.13. Foundation Medicine, Inc
18.14. Biocept, Inc.
18.15. Roche Holding AG
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
